BPC-157 mcg vs mg: Dosing Units Explained for BPC-157, TB-500, and GHK-Cu
This article is pending qualified medical review.
BPC-157 (a synthetic 15-amino-acid "pentadecapeptide" derived from a sequence in human gastric juice), TB-500 (a synthetic fragment of the naturally occurring protein thymosin beta-4), and GHK-Cu (a copper-binding tripeptide, glycine-histidine-lysine, found naturally in human plasma) are three distinct compounds that are frequently sold together as "healing peptides" but are dosed in different units and supported by different levels of evidence. None has an FDA-approved indication for any use as of this writing (2025); all human use outside of an IRB-approved trial is off-label, unregulated, or compounded from unapproved bulk material.
The most consequential practical fact on this page is a unit error, not a dosing recommendation: BPC-157 protocols are conventionally expressed in micrograms (mcg), while TB-500 protocols are conventionally expressed in milligrams (mg), a 1,000-fold difference. Mistaking one unit for the other on a vial label, a written protocol, or a compounding order produces either a massive overdose or a dose too small to have any plausible effect. That distinction is the one thing this page can state with confidence; the specific dose numbers below are extrapolations from animal research and unregulated off-label practice, not validated human dosing.
What is actually established, and what is not
- Established: BPC-157, TB-500, and GHK-Cu are chemically and structurally distinct molecules with different conventional dosing units (mcg vs mg vs mg/mL). None is FDA-approved for any human indication. Thymosin beta-4 and its fragments, including TB-500, are classified by the World Anti-Doping Agency under category S2 (peptide hormones, growth factors, and related substances) and are prohibited in competitive sport dated to the current WADA Prohibited List (wada-ama.org).
- Plausible but unproven in humans: Preclinical (mostly rodent) research has reported tissue-healing, gut-protective, and angiogenic effects for BPC-157 and thymosin beta-4 sequences, and cell-culture and topical studies have reported skin-related effects for GHK-Cu. Whether these effects translate to reliable, dose-predictable benefit in humans, at what dose, and with what safety margin, has not been established by controlled human trials for BPC-157 or TB-500.
- Not established: A validated human dose-response curve for BPC-157 or TB-500; long-term human safety data for any of the three compounds; equivalence between rodent allometric extrapolation and an effective human dose; safety or efficacy of combining BPC-157 and TB-500; and the specific numeric protocols (mcg per injection, mg per week, injection-site selection) that circulate in off-label and compounding-pharmacy literature. Treat any precise number you encounter for these compounds, including numbers on this page, as a starting point for discussion with a qualified prescriber, not a validated instruction.
A note on the source literature for this topic: many of the specific citations that circulate with BPC-157/TB-500/GHK-Cu dosing content online, including in earlier versions of pages like this one, cannot be independently verified against the paper they claim to describe, and some identifiers point to unrelated or mismatched publications. This draft removes those unverifiable specific citations rather than repeat them, and flags where a claim needs primary-literature verification before publication.
Why the mcg vs mg distinction matters for BPC-157
One milligram equals 1,000 micrograms. If a compounding order or a hand-written protocol is ambiguous about the unit, and someone reads "mg" where "mcg" was intended, the resulting dose is 1,000 times stronger than intended. Preclinical BPC-157 research has generally used doses in the low micrograms-per-kilogram range in rodents, and off-label human protocols circulating in the peptide community typically describe single injections in the low hundreds of micrograms. A milligram-scale BPC-157 injection is well outside anything described in the published animal literature and should be treated as a red flag, not a stronger dose.
Practical conversion reference:
| Written dose | Actual quantity |
|---|---|
| 200 mcg | 0.2 mg |
| 500 mcg | 0.5 mg |
| 1,000 mcg | 1.0 mg |
If a vial label, compounding pharmacy communication, or written protocol is unclear about mcg versus mg, do not draw or inject the product until the unit is confirmed in writing with the pharmacy or prescriber.
How BPC-157 injection doses are typically calculated off-label
Rodent studies of BPC-157 in tendon, ligament, and gastrointestinal healing models have generally used doses in the range of roughly 10 micrograms per kilogram of body weight, administered daily or twice daily for one to several weeks, depending on the model. Scaling a rodent dose to a human using standard allometric conversion factors is a common exercise in off-label peptide protocols, and it is the basis for the widely repeated "200 to 500 mcg per injection" figure for an adult. That figure is an extrapolation, not a human-validated dose, and no published human dose-finding trial establishes it.
A typical compounded BPC-157 vial is a lyophilized powder, commonly supplied at 5 mg total content. A general reconstitution approach used in practice:
- Add bacteriostatic water to the vial as directed by the compounding pharmacy (a common example is 2.5 mL added to a 5 mg vial, giving 2 mg/mL, or 2,000 mcg/mL).
- Calculate the injection volume for the intended microgram dose by dividing the dose by the concentration.
- Confirm the calculated volume against the markings on an insulin syringe before drawing.
Do not treat these steps as individualized dosing instructions. Reconstitution concentration, storage conditions, and syringe gauge should be confirmed directly with the dispensing pharmacy, and dosing decisions belong to a licensed prescriber who has evaluated the specific patient.
Whether BPC-157 should be injected systemically (subcutaneously or intraperitoneally in animal studies) versus locally near an injury site is unresolved. Preclinical ligament-healing studies have tested both routes, and no controlled human trial has compared injection sites directly.
Reconstituted peptide is generally handled like other compounded peptide products: refrigerated between roughly 2 and 8°C, used within a limited window (compounding pharmacies commonly cite about 28 days, though this is a pharmacy-specific stability claim rather than a published human pharmacokinetic finding), and discarded if cloudy or if repeatedly frozen and thawed.
Oral versus injectable BPC-157: what changes
Preclinical studies of BPC-157 given orally, in drinking water, in models of colitis and gastric ulceration have used doses far lower than injectable protocols, sometimes in the nanograms-per-kilogram range. This is consistent with the idea that oral peptides are subject to substantial breakdown in the gastrointestinal tract before any fraction reaches systemic circulation. The actual fraction of an oral BPC-157 dose that survives digestion and reaches systemic circulation in humans has not been formally measured in a published pharmacokinetic study.
The practical implication offered in off-label practice, not established by controlled trials, is that oral delivery may be more appropriate for gut-localized goals (where the peptide can act directly on the gastrointestinal lining) and less reliable for systemic musculoskeletal goals, where injectable delivery is more consistent with the preclinical dose-response pattern. This is a plausibility argument, not a demonstrated clinical outcome difference.
TB-500 dosing: milligrams, not micrograms
TB-500 is a synthetic fragment of thymosin beta-4 containing the actin-binding sequence found in the parent protein. Unlike BPC-157, TB-500 protocols in the off-label peptide literature are expressed in milligrams. Commonly cited structures include a higher "loading" dose for the first several weeks (on the order of a few milligrams per week, split into two injections) followed by a lower "maintenance" dose (roughly half that, once weekly). These figures come from off-label and gray-market protocol literature rather than a published, controlled human dose-finding trial of TB-500 itself.
It matters that TB-500 is a fragment, not the full thymosin beta-4 protein. Human trials of full-length thymosin beta-4 for wound healing exist in the published record, but a trial of the parent protein does not establish the dose, safety, or efficacy of the shorter TB-500 fragment in humans, and this page does not attach specific trial numbers, sample sizes, or p-values to TB-500 because the underlying identifiers require verification against the primary literature before they can be published as fact. If your protocol or a source you are reading cites a specific TB-500 trial with a precise result, ask for the original paper before relying on it.
TB-500 is injected subcutaneously in common practice, most often in the abdomen; intramuscular injection near an injured area is also used, but no controlled comparison of injection routes has been published.
TB-500, as a fragment of thymosin beta-4, falls under the WADA S2 category of prohibited peptide hormones and growth factors (WADA Prohibited List). Athletes subject to anti-doping testing should assume TB-500 use at any dose is a violation, and confirm current-year list status before use since prohibited-substance lists are updated annually.
GHK-Cu: topical and injectable dosing differ in evidence quality
GHK-Cu is a naturally occurring copper-binding tripeptide present in human plasma; plasma levels are reported to decline with age, and this decline has been proposed as one contributor to slower skin repair in older adults, though this is an observational association rather than a proven causal mechanism.
Topical GHK-Cu is the better-supported of the two delivery routes. Cosmetic and dermatology research has tested topical formulations generally in the range of 0.1 to 1 percent concentration (roughly 1 to 10 mg/mL), applied once or twice daily over weeks to months, with some controlled cosmetic studies reporting improvements in measures like fine lines or skin density compared with a vehicle control. Exact sample sizes, effect sizes, and statistical results from specific named trials are not reproduced here because the underlying citations require primary-source verification; a dermatology-focused review of copper peptide cosmetic trials should be consulted directly before citing specific numbers.
Injectable GHK-Cu is used in some aesthetic-medicine practices for scalp and facial applications, generally described in the literature as roughly 0.5 to 2 mg per injection site per session, or lower per-point doses (a fraction of a milligram) when distributed across many intradermal points for scalp protocols. This use is supported mainly by cell-culture (in vitro) data on gene expression changes and by small pilot studies or case series, not by a large controlled human trial. Systemic (non-topical, non-localized) GHK-Cu injection at higher doses has not been studied in human clinical trials; rodent toxicity data suggesting tolerability at high doses do not establish a human safety ceiling.
Stacking BPC-157 and TB-500
Combining BPC-157 and TB-500 is common in off-label performance-medicine practice on the theory that their proposed mechanisms are complementary: BPC-157 research has focused on nitric oxide signaling and growth-factor receptor pathways, while thymosin beta-4/TB-500 research has focused on actin-binding and cell-migration effects. No published human trial has tested the combination, and no stability data exist in the peer-reviewed literature for co-mixing the two peptides in a single syringe. Treat any specific combined protocol you encounter, including figures repeated across peptide forums and vendor sites, as unverified off-label practice rather than an evidence-based regimen.
Unit-check protocol before any injection
Before drawing any peptide dose, three checks catch most unit-transposition errors:
- Identify the unit on the vial label (mcg or mg), not just the total vial content. BPC-157 vials are commonly labeled by total milligram content but dosed in micrograms per injection; TB-500 vials are labeled and dosed in milligrams.
- Calculate the concentration after reconstitution, in the same unit you intend to dose in (convert to mcg for BPC-157 calculations).
- Cross-check the drawn syringe volume against the intended dose: intended dose divided by concentration should equal the volume you are about to inject. If it does not match, stop and recheck before injecting.
Comparison: BPC-157 vs TB-500 vs GHK-Cu dosing decisions
| Criterion | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Conventional dosing unit | Micrograms (mcg) | Milligrams (mg) | mg/mL (topical) or mg per site (injectable) |
| Typical off-label range | ~200-500 mcg per injection, once or twice daily | ~2-5 mg per week (loading), ~2-2.5 mg per week (maintenance) | Topical: ~1-5 mg/mL, 1-2x/day. Injectable: ~0.5-2 mg per site |
| Strongest available evidence type | Rodent tissue-healing and gastric-protection studies | Human trials exist for the parent protein (thymosin beta-4), not for the TB-500 fragment specifically | Topical: cosmetic/dermatology controlled studies. Injectable: cell-culture and case-series data |
| Route with best support | Systemic injection in animal models (route-to-route comparison not settled) | Subcutaneous injection (route comparison not controlled) | Topical, for cosmetic skin endpoints |
| FDA status (2025) | No approved indication; not on FDA's approved bulk-compounding substances list per current FDA guidance, which should be reconfirmed before use | No approved indication | No approved indication as a drug; some GHK-Cu is marketed as a cosmetic ingredient, which is a different regulatory category than a drug claim |
| WADA status | Not separately listed by name, but growth-factor-acting peptides in this class fall under scrutiny; confirm against the current list | Explicitly covered under S2 (peptide hormones/growth factors) via thymosin beta-4 | Not a WADA-prohibited category as a topical cosmetic ingredient; confirm if used by injection in an athlete |
| Where the evidence gap matters most | No human dose-finding trial exists; extrapolated doses are a best guess, not a validated dose | Human safety/efficacy data are for a different, longer molecule than the one being sold | Injectable use has far less support than topical use; do not assume topical evidence justifies injectable dosing |
| Best-fit circumstance for current evidence | Reader specifically researching off-label, physician-supervised use for a tendon or gut-healing question, aware of animal-only evidence | Reader aware they are outside competitive sport, or an athlete confirming they must avoid it entirely | Reader interested in topical skin-aging or wound-support products, where evidence is comparatively stronger than for injectable use |
This table is a decision-support summary, not a treatment recommendation. Every row involving a specific numeric range describes off-label or preclinical practice; none of these numbers has been validated by an FDA-reviewed human dose-finding trial.
Regulatory and safety context (verify dates before publishing)
As of early 2025, BPC-157, TB-500, and GHK-Cu carry no FDA-approved therapeutic indication. Products marketed for injection or oral use as these peptides in the United States are typically sold as research chemicals or compounded preparations, not as FDA-approved drugs. The FDA has taken positions restricting compounding of certain research peptides, including reported action affecting BPC-157's eligibility for compounding under Sections 503A/503B of the Federal Food, Drug, and Cosmetic Act; the exact current status of any specific peptide on FDA's bulk drug substance lists changes over time and should be confirmed against FDA's current compounding guidance before this claim is published as a stated fact.
No controlled human safety trial has been published for BPC-157 or TB-500. Reported animal findings, such as transient blood-pressure changes with high-dose intravenous BPC-157 in rodents, do not establish a human safety profile, and the absence of widely reported serious adverse events in off-label human use is not the same as documented safety. Anyone using these compounds off-label should have a plan for what symptoms (unexplained pain, swelling, signs of infection at an injection site, allergic reaction, or unusual systemic symptoms) warrant contacting a prescriber or seeking urgent care rather than continuing the protocol.
Storage and reconstitution quality
A correctly measured dose still under-delivers if the peptide has degraded before injection. General practices used by compounding pharmacies for peptide products like BPC-157 and TB-500 include storing lyophilized (freeze-dried) powder frozen until reconstitution, refrigerating the reconstituted solution between roughly 2 and 8°C, using it within a pharmacy-specified window, discarding any solution that turns cloudy or shows particulate matter, and using a fine needle (23-25 gauge) to draw from the vial to reduce coring of the stopper. GHK-Cu's copper-coordination structure is generally considered more chemically stable after reconstitution than a linear peptide like BPC-157, but formal peer-reviewed stability data for compounded GHK-Cu solutions are limited; treat pharmacy-specific shelf-life claims as pharmacy-specific, not universal.
Frequently asked questions
What is the difference between BPC-157 mcg and mg dosing?
How many mcg of BPC-157 do off-label protocols typically use?
What is the standard TB-500 dosing protocol?
What concentration is GHK-Cu for topical use?
Can BPC-157 and TB-500 be taken together?
Is BPC-157 legal to buy and use?
Does BPC-157 need to be injected near the injury site?
References
- US Food and Drug Administration. Drug approvals database and current compounding guidance. https://www.accessdata.fda.gov/scripts/cder/daf/, confirm current bulk-substance and compounding status for BPC-157 before citing.
- World Anti-Doping Agency. Current Prohibited List, category S2 (peptide hormones, growth factors, and related substances). https://www.wada-ama.org/en/prohibited-list, confirm current-year list before citing TB-500's status.
A note for the editor: the source draft for this page contained multiple specific PubMed identifiers attached to precise claims (exact sample sizes, p-values, and a direct quotation attributed to a named study). Those identifiers could not be verified against the claims made and, in at least one case, the same identifier was used to support two different and inconsistent claims. They have been removed rather than carried forward. Before publication, an editor with primary-literature access should locate and verify specific studies for: rodent BPC-157 dose-response data, the human thymosin beta-4 pressure-ulcer trial, and the topical GHK-Cu cosmetic trial, and reintroduce exact figures only once each citation is confirmed to match its claim.